Emerging Challenges in Primary Care: GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management
|
|
- Heather Logan
- 6 years ago
- Views:
Transcription
1 Emerging Challenges in Primary Care: 2017 GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management 1
2 Faculty Richard S. Beaser, MD Senior Staff Physician, Medical Director of Professional Education Joslin Diabetes Center Associate Clinical Professor of Medicine Harvard Medical School Boston, MA Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY Richard Pratley, MD Senior Investigator and Diabetes Program Head Translational Research Institute for Metabolism and Diabetes Research and Education Director, Florida Hospital Diabetes Institute Orlando, FL Jeff Unger, MD, ABFM, FACE Director, Unger Primary Care Medical Group Rancho Cucamonga, CA Mark Stolar, MD Associate Professor of Clinical Medicine Feinberg School of Medicine Northwestern University Chicago, IL 2
3 Disclosures Richard S. Beaser, MD has no financial relationships to disclose. Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Novo Nordisk, and Shire. Dr. Busch also serves as a researcher for Astra Zeneca, Novo Nordisk, Janssen, and Amgen. Mark Stolar, MD serves as a speaker/advisory board member for Astra Zeneca. Richard Pratley, MD serves as a speaker/consultant for AstraZeneca. Dr. Pratley also serves as a consultant for Boehringer-Ingelheim, GlaxoSmithKline, Hanmi Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Inc., and Ligand Pharmaceuticals, Inc. Additionally, Dr. Pratley performs research under contract for for Lexicon Pharmaceuticals, Sanofi-Aventis US, LLC, Lilly, Merck, and Takeda. Dr. Pratley performs research, is a speaker and consultant for Novo Nordisk. All honoraria and fees are directed to a non-profit. Dr. Pratley does not receive any direct compensation for these activities. Jeff Unger, MD, ABFM, FACE serves on the advisory board for Abbott, Novo Nordisk, Janssen, and Intarcia. 3
4 Learning Objectives Discuss the role of postprandial hyperglycemia in the pathogenesis of diabetic complications. Incorporate GLP-1 RA therapy into practice to reduce post-prandial hyperglycemia and decrease glycemic variability. Compare GLP-1 RAs for glycemic efficacy and differential impact on postprandial glycemic control. Discuss various GLP-1 RA combination strategies with, or as a possible alternative to, basal insulin in the diabetic patient not at glycemic target. 4
5 PRE-TEST QUESTIONS 5
6 Pre-test ARS Question 1 At about what level of A1C does postprandial glucose account for >50% of total A1C? 1. ~7% 2. ~8% 3. ~9% 4. ~10% 6
7 Pre-test ARS Question 2 Comparing the differences between shorter and longer-acting GLP-1 receptor agonists, which of the following statements is true? 1. Longer-acting have a greater impact on reducing postprandial glucose 2. Longer-acting have a greater impact on fasting glucose 3. Shorter acting have a greater impact on increasing fasting insulin secretion 4. Shorter acting have a greater impact on fasting glucose 7
8 Pre-test ARS Question 3 The advantages of combining GLP-1 receptor agonists with basal insulin include all of the following, EXCEPT: 1. Less risk for weight gain compared to insulin alone 2. Reductions in both fasting and postprandial glucose levels 3. Significantly lower incidence of hypoglycemia compared to insulin alone 4. Potential for reduced doses of basal insulin when GLP-1 RA added to insulin therapy 8
9 Pre-test ARS Question 4 A 49-year-old man with 10-year history of T2DM and NSTEMI 2 years ago works on a farm and has long active days. His A1C is 7.8%, FBG mg/dl and PPG mg/dl. Meds include metformin 1000 mg bid and basal insulin 38 U qam. Which of the following might be appropriate to manage hyperglycemia and cardiovascular risk? 1. Add sulfonylurea 2. Add rapid-acting insulin before each meal 3. Discontinue basal insulin and start GLP-1RA 4. Add GLP-1RA and reduce dose of basal insulin 9
10 Pre-test ARS Question 5 When adjusting therapy in patients with type 2 diabetes, how often do you consider using GLP-1 receptor agonists in combination with basal insulin: 1. Never 2. Rarely 3. Sometimes 4. Often 5. Always 10
11 Pre-test ARS Question 6 Please rate your confidence in your ability to utilize GLP-1RAs in clinical practice: 1. Not at all confident 2. Slightly confident 3. Moderately confident 4. Pretty much confident 5. Very confident 11
12 ADA 2016: Standards of medical care in diabetes Initial monotherapy Healthy eating, weight control, increased physical activity Metformin Two-drugs combined SU TZD DPP-4 i SGLT2i GLP-1 RA Insulin (basal) Threedrugs combined Combined injectable therapy TZD DPP-4i SGLT2i GLP-1 RA Insulin SU DPP-4i SGLT2i GLP-1 RA Insulin SU TZD SGLT2i Insulin SU TZD DPP-4i Insulin SU TZD Insulin Basal insulin + Mealtime insulin or GLP-1 RA Escalate therapy at 3 months if target not achieved DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; SU, sulfonylurea; TZD, thiazolidinedione ADA. Diabetes Care. 2016;39(Suppl. 1):S1 S2. TZD DPP-4i SGLT2i GLP-1 RA 12
13 Likelihood of Monotherapy Failure in ADOPT 40 Glyburide Cumulative Incidence of Fasting Glucose Greater than 180 mg/dl P<0.001 Metformi n P<0.001 Rosiglitazon e N = N Eng J Med 2006;355:
14 Ominous Octet DeFronzo RA. Diabetes. 2009;58:
15 Progressive β-cell Dysfunction Is a Key Driver of Progressive Dysglycemia in T2D By the time of diabetes onset, up to 80% of β-cell function may be lost 1,2 Insulin Insulin Resistance Resistance Deteriorating β-cell function is partially driven by the incretin defect PPG FPG β-cell Function Insulin Secretion Insulin Production Normal Glucose Tolerance Impaired Glucose Tolerance Diagnosis Severity of Glucose Intolerance Time in Years PPG indicates postprandial plasma glucose; FPG, fasting plasma glucose; T2D, type 2 diabetes; 1. Defronzo RA. Diabetes 2009;58: ; 2. Fehse F, et al. J Clin Endocrinol Metab 2005;90: ; Figure adapted from Kendall DM, et al. Am J Med 2009;122(6 Supp):S37-S50 15
16 Fasting vs Postprandial Glucose Contribution to HbA1c Contribution 100% 80% 60% 40% 20% 30% 70% 50% 55% 60% 70% 50% 45% 40% 30% 0% < >10.2 HbA1c Range (%) Postprandial Plasma Glucose Fasting Plasma Glucose Monnier L et al. Diabetes Care. 2003;26:
17 GLP-1 RAs Mimic and Extend Actions of Endogenous GLP-1 Inactivation Concentration Endogenous GLP-1 RA Rapid Cleavage by DPP-4 Renal elimination Physiologic GLP-1 RAs Delayed Resistance to DPP-4 Resistance to renal filtration Pharmacologic Timing of effects Prandial/early postprandial Prandial/early postprandial Fasting Meier JJ. Nat Rev Endocrinol Dec;8(12):
18 GLP-1 RA Exenatide 5-10 mcg twice daily (Byetta 2005) 2 mg once weekly (Bydureon 2012) Liraglutide mg daily (Victoza 2010) 3 mg daily (weight loss indication, Saxenda 2014) Albiglutide mg once weekly (Tanzeum 2014) Dulaglutide mg once weekly (Trulicity 2014) Lixisenatide 10-20mcg daily (Adlyxin 2017) 18
19 GLP-1 RA Exenatide, Exenatide LAR, Liraglutide, Albiglutide, Dulaglutide, Lixisenatide Mechanism Primary physiological action(s) Advantages Limitations Cost Activates GLP-1 RA glucose-dependent insulin secretion glucose-dependent glucagon secretion Satiety Slows gastric emptying Postprandial glucose excursions Weight Patient training requirements (injectable therapy) Gastrointestinal side effects (nausea, vomiting [less with longer-acting agents]) Hypoglycemia possible when used with insulin, if insulin doses are not reduced High (relative to other generic agents, ie metformin) Inzucchi SE, et al. Diabetes Care
20 Case 1: Meet Cherise Cherise is a 38 year old African American female with a 5 yr history of type 2 diabetes on maximum SFU and metformin. She could not tolerate TZDs due to edema and refused to start insulin. Her HbA1c for the past 2 years has been between 7.9% and 8.8%. Most recent: 9.0% PMH sig. for dyslipidemia, hypertension and central obesity (BMI 43). Her weight is not a concern for her. Strong family history of type 2 diabetes as her mother and grandmother are both on dialysis and a maternal aunt recently died of a CVA 20
21 ARS Question Which of the following might help Cherise improve her glycemic control? 1. Recommend GLP-1RA and show her an injection pen 2. Tell her that she will need insulin if she does not lose significant weight 3. Add DPP-4 inhibitor and consider SGLT-2 inhibitor if response insufficient 4. Recommend full basal-bolus regimen and remind her of her family history of kidney disease 21
22 Case 1: Helping Cherise Succeed (Current rx metformin 2000 max SU) Her PCP was concerned about the high HbA1C and recommended insulin, but she refused to start insulin as it made her too anxious and wanted to work harder on fitness and a medication that will help with weight loss. She agreed to start dulaglutide once weekly. She developed nausea for the first 3 weeks post injection and stopped the medication. She admits giving an injection was not a big deal, but stated taking insulin just made her nervous. Over the next two months she tried her best to diet and exercise but follow up HbA1c was still 8.6%. How can you now effectively transition Cherise to accepting insulin therapy or restarting her GLP-1 RA? 22
23 Barriers to Injectables: The CLINICIAN Side of the Equation Misperceptions The need to advance Rx is never-ending (therapeutic fatigue) Insulin: most appropriate for end-stage Rx Patients don t want to use injectables Reality-based Concerns Time demands of instructing patients about injections Unfamiliarity with the variety of devices (e.g., various pens) Misplaced Blame If only the patient would exercise and lose weight, they wouldn t need insulin Knowledge gaps Role of glucotoxicity in disease progression and therapeutic failure Typical weight changes (gain): insulin Typical weight changes (loss): GLP-1 RA Familiarity with ADA/EASD and AACE Guidelines 23
24 Suggestions for Overcoming Fear of Injections Dry run injection (Insert needle without injecting drug) Reinforce that injection is relatively painless Injection is into fatty tissue versus muscle Reinforce that injection is easy Injection devices are quick and easy-to-use Have pen available for demonstration 24
25 Patient-level meta-analysis: HbA1c reduction across baseline categories % >7.5% 8.0% >8.0% 8.5% >8.5% 9.0% >9.0% Change in HbHbA1c (%) from baseline to 26 weeks * ** ** ** ** ** ** * * **** *** * 2.0 Liraglutide 1.8 mg Sitagliptin Glimepiride Rosiglitazone Exenatide Glargine HbA1c, glycosylated haemoglobin *p<0.05, **p<0.01, ***p<0.001, ****p< vs. liraglutide 1.8 mg Henry et al. Endocr Pract 2011;17:
26 HbA1c and Weight Change with Sitagliptin vs. Dulaglutide Once Weekly added to Metformin after 52 weeks (AWARD-5) LS Change in HbA1c (%) HbA1c Reductions (%) Dulaglutide 1.5 mg P<.001 Nauck M, et al. Diabetes Care Dulaglutide 0.75 mg Sitagliptin 100 mg LS Change in Weight Weight Loss (kg) Dulaglutide 1.5 mg P< Dulaglutide 0.75 mg Sitagliptin 100 mg 26
27 GLP-1 RA Pharmacologic Activity Is Higher With GLP-1 RAs Than With DPP-4 Inhibitors Plasma Level (pm) Baseline Sitagliptin Exenatide twice daily 7 15 Endogenous GLP-1 RA Activity 64 Added GLP-1 RA Activity N=61 metformin-treated, evaluable patients. 27 DeFronzo RA, et al. Curr Med Res Opin
28 Comparing GLP-1 RAs Shorter-Acting vs Longer-Acting Formulations Compounds Shorter Acting Exenatide BID, lixisenatide Longer Acting Albiglutide, dulaglutide, exenatide QW, liraglutide, semaglutide a Half-life 2-5 hours 12 hours to several days Effects FPG reduction Postprandial hyperglycemia reduction Fasting insulin secretion stimulation Glucagon secretion Weight reduction Potential for nausea Modest Strong Modest Reduction Yes Yes Strong Modest Strong Reduction Yes Yes Clinical Pearl: Select GLP-1 RAs for T2DM based on the patient s hyperglycemia profile and preferences. a Not approved by the FDA for use in the United States. Brunton S. Int J Clin Pract. 2014;68(5): ; Fonseca VA. Clin Ther. 2014;36(4): ; Kalra S. Diabetes Ther. 2014;5(1):
29 Effects of Exenatide BID vs Exenatide QW on PPG Exenatide QW (n = 129) Exenatide BID (n = 130) PPG (mmol/l) Baseline Week 30 Pre Post Pre Post Pre Post 03:00 Breakfast Lunch Dinner Data presented are means ± SE PPG taken from SMBG profile Drucker DJ et al. Lancet 2008;372: PPG = post-prandial plasma glucose SMBG = self-monitored blood glucose
30 Head-to-Head Trials Comparing Efficacy of GLP-1 RAs EXN BID 10 mcg LIRA 1.8 mg EXN QW 2.0 mg ALBI 50 mg DULA 1.5 mg 1 Δ A1C, % LEAD-6 1 DURATION-5 2 DURATION-6 3 HARMONY-7 4 AWARD-1 5 AWARD a -1.1 Added to MET ± SU -0.9 a -1.6 Added to Drug-naïve or MET ± SU ± TZD a,b Added to Drug-naïve or MET ± SU ± TZD b Added to MET ± SU ± TZD a Added to MET ± TZD c Added to MET 1. Buse JB, et al. Lancet. 2009;374:39-47; 2. Blevins T, et al. J Clin Endocrinol Metab. 2011;96: ; 3. Buse JB, et al. Lancet. 2013;381: ; 4. Pratley R, et al. Lancet Diabetes Endocrinol. 2014;2: ; 5. Wysham C, et al. Diabetes Care. 2014;37: ; 6. Dungan K, et al. Lancet. 2014; 384(9951): a P <.05 between groups. b Noninferiority vs LIRA not met. c DULA noninferior to LIRA, P <.0001.
31 Patient Education Talking Points for GLP-1 RA Instruct on good injection technique GI disturbances May cause hypoglycemia when used with sulfonylureas or insulin Exenatide twice daily or liraglutide: Prime or set up pen device only once when medication is first started Store refrigerated until pen is in use, then keep at room temperature Discuss signs and symptoms of pancreatitis when initiating therapy Triplitt CL, et al. Pharmacotherapy: A Pathophysiologic Approach
32 ARS Question Which of the following can help minimize gastrointestinal side effects when initiating GLP-1RA? 1. Eat smaller meals and more slowly 2. Use short-term antiemetic therapy for select patients 3. Increase dose slowly, especially shorter-acting agents 4. All of the above 32
33 Nausea and Vomiting Pooled Results From Placebo-Controlled Trials Medication Nausea Incidence, % Vomiting Incidence, % Albiglutide Dulaglutide Exenatide twice daily Exenatide once weekly Liraglutide Lixisenatide 6 25% 10% Potential approaches to reduce risks for nausea and vomiting 3,6 Educate patients on meal size, eating pace, and dose timing relative to meals Use incremental dosing, particularly with shorter-acting agents Prescribe short-term antiemetic therapy for select patients Clinical Pearl: Recommend that patients eat smaller meals and more slowly when initiating treatment with a GLP-1 RA. 1. Albiglutide prescribing information. Prescribing_Information/Tanzeum/pdf/TANZEUM-PI-MG-IFU-COMBINED.PDF. Accessed May 29, 2015; 2. Dulaglutide prescribing information. Accessed May 29, 2015; 3. Drugs@FDA /021773s029s030lbl.pdf. Accessed May 29, 2015; 4. Drugs@FDA. Accessed May 29, 2015; 5. Drugs@FDA. Accessed May 29, 2015; 6. Ellero C, et al. Diabet Med. 2010;27: Drugs@FDA Accessed April 7,
34 Weight Change (kg) Weight Loss With GLP-1 RAs Not Driven by Gastrointestinal Liraglutide (Meta-Analysis/6 26-Week Trials) No NVD a,b a,b PBO 1.2 mg LIRA 1.8 mg LIRA P<0.05 Adverse Events a Some NVD P< a a,b Exenatide (30-Week DURATION-1 Trial) 2 In a 82-week exenatide completer cohort, weight loss was 1) similar across degrees of nausea, 2) progressive despite stable nausea incidence, and 3) unlikely to be driven by nausea No Nausea -3.1 EXN QW EXN BID Nausea -4.1 NVD, nausea, vomiting, diarrhea; PBO, placebo. a P<0.05 vs baseline; b P<0.05 vs placebo. 1. Russell-Jones D, et al. 70th ADA Scientific Sessions. 2010;1886-P; 2. Drucker DJ, et al. Lancet. 2008;372(9645): ; 3. Blonde L, et al. Diabetes Obes Metab. 2006;8(4):
35 GLP-1 RAs Added to Multiple Oral Agents: Comparisons With Basal Insulin 0 MET + SU (N=535) OADs (N=235) MET + GLIM (N=576) MET ± SU (N=456) 4,* 5, MET ± SU (N = 216) A1C (%) Noninferior vs. insulin P=NS vs. insulin P=.0015 vs. insulin P<.05 vs. insulin P<.0001 vs. insulin GLAR EXN BID LIRA EXN QW IDET * 70% on MET monotherapy background 70% on MET + SU background 1 Heine R, et al. Ann Intern Med. 2005;143: ; 2 Davies M, et a. Diabetes Obes Metab. 2009;11: ; 3 Russell-Jones D, et al. Diabetologia. 2009;52: ; 4 Diamant M, et al. Lancet. 2010;375: ; 5 Davies M, et al. Diabetes Care. 2013;36:
36 GLP-1 RAs vs Basal Insulin Change in HbA1c From Baseline, % st 2nd 3rd 4th Exenatide QW Glargine st 2nd 3rd 4th Liraglutide Glargine -4-4 LEAD-5, Liraglutide Effect and Action in Diabetes. Buse JB, et al. Diabetes Obes Metab. 2015;17(2): ; Diamant M. Lancet Diabetes Endocrinol. 2014;2(6): ; Russell-Jones D, et al. Diabetologia. 2009;52(10):
37 Intensifying Treatment with Combination Injectable Therapy When added to oral antihyperglycemic therapy, basal insulin alone may not be sufficient for reaching HbA1c goals, especially as fasting plasma glucose approaches normal levels Combination injectable therapy Basal insulin Essential component of the treatment strategy when HbA1c target is not achieved despite intensive therapy with 3 antihyperglycemic agents Options for intensified therapy Basal-bolus insulin Basal insulin + GLP-1 RA 37 Inzucchi SE et al. Diabetes Care. 2015;38: ; Woerle HJ et al. Diabetes Res Clin Pract. 2007;77:
38 Not at Goal: Intensifying Therapy Beyond OAD + Basal: Meet Dave 52 y/o Irish American Construction Foreman Type 2 diabetes for 8 years. Meds: metformin 1000 mg bid, glipizide 10mg bid and levemir 80 units bid. FBS mg/dl. Sometimes misses evening insulin dose when falling asleep on the couch watching TV. Morning glucose seems no different when he misses his second dose. He doesn t check his blood sugar often in the evening because it was over 240 on the few times he checked. 38
39 More about Dave: Dave works 5-10 hour shifts during season and has to drive an hour each way to work. On his days off he helps his brother remodel a house. He has no other defined exercise as his arthritis of both knees is becoming quite symptomatic. His BMI is His mother and sisters are all obese and all have type 2 diabetes, but only 2 of 5 are on insulin. He is hypertensive, hypercholesterolemic, and is an ex smoker having quit 5 years ago when his grandchildren were born. 39
40 Laboratory Assessment HbA1c 8.9% FBS 165 mg/dl Creatinine 1.5 mg/dl Microalbumin 75 mg/ g creat N <30 Tc 190 mg/dl HDL 35mg/dl TG 190mg/dl LDL 117mg/dl 40
41 ARS: Which of the following statements about Dave is correct? 1. Given his high CV risk, a GLP-1 RA or SGLT-2 inhibitor is recommended as part of his therapy 2. His beta cell function is gone since he is not responding to glipizide 3. Bolus insulin would control postprandial glucose in this patient more effectively than a GLP-1 RA 4. Addition of an SGLT-2 inhibitor could get this patient close to target 41
42 ARS: What is the next best step for Dave to get him to goal? 1. Add an SGLT-2 inhibitor 2. Add pioglitazone 3. Discontinue glipizide and add bolus insulin 4. Discontinue glipizide and add a GLP-1 RA 5. 2 and and 4 42
43 Combining GLP-1 RA and Basal Insulin Complementary actions Simple to initiate Basal insulin analogs Control nocturnal hyperglycemia and FPG Lower hypoglycemia risk than NPH Can cause weight gain Achieve HbA1c target in ~50% a GLP-1 RAs Simple to initiate Can control FPG and PPG Do not impair α-cell response to hypoglycemia (reduce risks of severe hypoglycemia) Weight-lowering Achieve HbA1c target in ~60% a Additive effects Potential for better overall HbA1c control a Percentage achieving <7% across baseline HbA1c quartiles for liraglutide and exenatide once weekly vs insulin glargine. Buse JB, et al. Diabetes Obes Metab. 2015;17: ; Holst JJ, Vilsbøll T. Diabetes Obes Metab. 2013;15:3-14; Vora J, et al. Diabetes Metab. 2013;39:
44 After Basal Insulin, Once-Weekly GLP-1 RA vs. Three Times Daily Prandial Insulin HbA1c Control 44 Rosenstock J, et al. Diabetes Care
45 After Basal Insulin, Once-Weekly GLP-1 RA vs. Three Times Daily Prandial Insulin Weight Rosenstock J, et al. Diabetes Care
46 Bolus Insulin vs GLP-1 RA in Combination with Optimized Basal Insulin + Metformin 3 Change in Key Endpoints* Exenatide BID Lispro TID 50 Safety *P<.001 for all key endpoints Percent of Patients Diamant M, et al. Diabetes Care. 2014;37;
47 GLP-1 RAs and Basal Insulin in T2DM Management: Complementary and Additive Features Basal insulin Primary effects Fasting glucose Interprandial glucose GLP-1 RA Postprandial glucose excursions Fasting glucose Mechanism Hepatic glucose production Glucose-dependent insulin secretion Non-glucose dependent endogenous insulin Glucagon secretion Insulin concentration Glucagon secretion Hepatic glucose production Gastric emptying Satiety Food intake Effect on weight Body weight Body weight Modified from Balena R et al. Diabetes Obes Metab. 2013;15:
48 Step-wise Process for Implementing GLP-1 RA and Basal Insulin Combination Therapy Identify patient who is not at HbA1c target despite oral antihyperglycemic medications and basal insulin > units/kg or appropriately titrated to morning glucose control* Discuss with patient the most common potential side effects. Consider reducing basal insulin dose by 20 % if HbA1c is < 8 % to minimize hypoglycemia risk Encourage patient to regularly self-monitor blood glucose and log the results Report any hypoglycemia (< 80 mg/dl) events for adjustment of insulin Teach the patient proper injection technique and dosing based on specific device Arrange a follow-up visit in approximately 1 month to evaluate treatment efficacy and to assess the patient for possible side effects *Chance of success may be maximized if HbA1c is within percentage points of target. Rhinehart AS. Clin Diabetes. 2015; 33(2):
49 Dave: Using Combination Injectable Therapy Dave and his PCP agreed that more insulin was not likely to be effective and he admitted that sometimes he took less insulin as he was afraid of such high doses. Liraglutide once daily was initiated and glipizide discontinued. At his six week follow-up, he was tolerating the medication well and HbA1c had already decreased from 8.9% to 8.2%. The dose was increased to 1.8 mg. At his three month recheck, HbA1c was down to 7.6% and Dave had lost six lbs. What now is more important? Further glycemic lowering or reducing CV risk further? 49
50 CVD is the Leading Cause of Death in People With T2DM Years of life lost in people with diabetes compared with peers without diabetes 1,a Years of Life Lost Men Nonvascular deaths Vascular deaths Age, years Women Mortality risk associated with diabetes (N=820,900) 1 Hazard Ratio (95% CI) for Diabetes vs No Diabetes CV death All-cause mortality a Information on diabetes type (ie, type 1 or 2) was generally not available, although participants' ages suggest that a large majority with diabetes would have T2DM (in high-income countries, up to 91% of adults with diabetes have T2DM) Seshasai SR, et al. N Engl J Med. 2011;364(9): ; 2. International Diabetes Federation. IDF Diabetes Atlas, 7th edition. Brussels, Belgium: International Diabetes Federation,
51 Potential Cardio protective MoA of GLP-1RA BP, blood pressure; GLP-1, glucagon-like peptide-1; GLP-1RA, glucagon-like peptide-1 receptor agonist; MoA, mode of action 51
52 ELIXA Lixisenatide in Patients With T2DM After ACS Patients Experiencing Primary Outcome a, % Lixisenatide Placebo HR, 1.02 (95% CI, 0.89, 1.17) P<0.001 for noninferiority P=0.81 for superiority Months No significant between-group differences in the rates of hospitalization or death a Primary outcome: CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for UA. N=6068 patients with T2DM who had a myocardial infarction or had been hospitalized for UA within the previous 180 days. Pfeffer MA, et al. N Engl J Med. 2015;373(23):
53 LEADER Liraglutide in T2DM With High CV Risk Patients With Event, % Primary Outcome a HR, 0.87 (95% CI: 0.78, 0.97) P<0.001 for noninferiority P=0.01 for superiority Placebo Liraglutide CV-Related Death HR, 0.78 (95% CI: 0.66, 0.93) 10 P=0.007 Placebo Liraglutide Months Since Randomization 5 0 Death From Any Cause HR, 0.85 (95% CI: 0.74, 0.97) P=0.02 Placebo Liraglutide a Composite of death from CV causes, nonfatal myocardial infarction, or nonfatal stroke. N=9340 patients with T2DM and high CV risk. Marso SP, et al. N Engl J Med. 2016;375(4):
54 Patients With Event, % SUSTAIN-6 Semaglutide in T2DM With High CV Risk Primary Outcome a Nonfatal Stroke Death From CV Causes Hazard ratio, 0.74 (95% CI, ) P<0.001 for noninferiority P=0.02 for superiority Placebo Semaglutide Hazard ratio, 0.61 (95% CI, ) P=0.04 Placebo Semaglutide Weeks Since Randomization a Composite of death from CV causes, nonfatal myocardial infarction, or nonfatal stroke. N=3297 patients with T2DM (A1c 7.0%) who were 50 years old with established CV disease or chronic kidney disease (Stage 3 or worse) OR were 60 years old with 1 CV risk factor were randomized to placebo or semaglutide 0.5 mg or 1.0 mg once weekly. Marso SP, et al. N Engl J Med Sep 15. [Epub ahead of print] Hazard ratio, 0.98 (95% CI, ) P=0.92 Placebo Semaglutide
55 Rationale for GLP-1 RA and Insulin The combination of a GLP-1 RA and insulin may be highly effective for optimal glucose control, ameliorating the adverse effects often associated with insulin. Data from clinical studies support the therapeutic potential of GLP-1 RA-insulin combination therapy, typically showing beneficial effects on: glycemic control body weight low incidence of hypoglycemia in established insulin therapy, facilitating reductions in insulin dose 55
56 GLP-1 RA/Basal Insulin Fixed-Ratio Combination 10 IDegLira IDeg Lira 1.8 mg Initial A1c 8.3 Final A1c A1c, % a a Total Trial Population a a a a a > a > Baseline A1c Category, % a a >9.0 n= a P<0.01. N=1660 insulin-naïve adults with T2DM (mean A1c, 8.3%; mean BMI, 31.2 kg/m 2 ) uncontrolled on oral agents assigned to IDegLira, insulin degludec, or liraglutide 1.8 mg daily (DUAL I Extension). Gough SC, et al. Lancet Diabetes Endocrinol. 2014;2(11): ; Rodbard HW, et al. Diabetes Obes Metab. 2016;18(1):
57 Fixed-Ratio IGlarLixi vs Glargine/GlarLixi Add-on to Metformin in T2DM a P=0.013; b P< vs glargine; c IGlarLixi formulation: insulin glargine 2 U/lixisenatide 1 µg. LOCF, last observation carried forward; LS, least squares. Mean Change in A1c ± SE, % IGlarLixi (n=161) Glargine (n=162) LS mean difference, -0.17% a 95% CI, , Sc LOCF Weeks c Mean Change in Body Weight ±SE, kg IGlarLixi (n=161) Glargine (n=162) LOCF Visit Symptomatic hypoglycemia ( 70 mg/dl): 22% with IGlarLixi vs 23% with glargine Incidence of nausea/vomiting was 7.5%/2.5% with IGlarLixi c b Rosenstock J, Diamant M, Aroda VR, Silvestre L, Souhami E, Zhou T, Perfetti R, Fonseca V; LixiLan PoC Study Group.. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. Diabetes Care Sep;39(9): doi: /dc Epub 2016 Jun 9. PubMed PMID: ; PubMed Central PMCID: PMC
58 GLP-1 RA/Basal Insulin Fixed-Ratio Combination Confirmed Hypoglycemia d Events Per 100 Patient-Years c a NS a b IDegLira IDeg Lira 7.5 > > >9.0 Total Trial Population Baseline A1c Category, % 5 severe hypoglycemic episodes reported (3 in 825 IDegLiratreated patients and 2 in 412 insulin degludec-treated patients) Fewer patients in the IDegLira group than in the liraglutide group reported GI adverse events (nausea, 8.8% vs 19.7%) a NS a a a a P<0.0001; b P=0.001; c P<0.05; d Confirmed hypoglycemia defined as of episodes requiring assistance (severe), or episodes in which self-monitored plasma glucose level was <3.1 mmol/l, irrespective of symptoms. N=1660 insulin-naïve adults with T2DM (A1c, 8.3%; BMI, 31.2 kg/m 2 ) uncontrolled on oral agents. Gough SC, et al. Lancet Diabetes Endocrinol. 2014;2(11): ; Rodbard HW, et al. Diabetes Obes Metab. 2016;18(1):
59 Intensifying Diabetes Therapy: Utilizing GLP-1 RA Effectively The need for insulin providing therapies is intrinsic in a chronic disease that progresses from relative to absolute insulin deficiency over time. Postprandial hyperglycemia plays an important and often unmonitored and undertreated role in the progression of diabetes. Use of basal insulin at bedtime is an effective means of lowering fasting and diurnal glycemia but does not address postprandial needs. The need for basal insulin implies deficiency post prandially as well. GLP-1 RA analogues and short acting insulin both meet that oft unmonitored need but with very different effects on hypoglycemia weight gain and beta cell function. GLP-1 RA analogues are a very effective means of providing endogenous insulin and are a very effective entry into injectable therapy as well as adjunct to basal insulin when intensified therapy is needed. 59
60 POST-TEST QUESTIONS 60
61 Post-test ARS Question 1 At about what level of A1C does postprandial glucose account for >50% of total A1C? 1. ~7% 2. ~8% 3. ~9% 4. ~10% 61
62 Post-test ARS Question 2 Comparing the differences between shorter and longer-acting GLP-1 receptor agonists, which of the following statements is true? 1. Longer-acting have a greater impact on reducing postprandial glucose 2. Longer-acting have a greater impact on fasting glucose 3. Shorter acting have a greater impact on increasing fasting insulin secretion 4. Shorter acting have a greater impact on fasting glucose 62
63 Post-test ARS Question 3 The advantages of combining GLP-1 receptor agonists with basal insulin include all of the following, EXCEPT: 1. Less risk for weight gain compared to insulin alone 2. Reductions in both fasting and postprandial glucose levels 3. Significantly lower incidence of hypoglycemia compared to insulin alone 4. Potential for reduced doses of basal insulin when GLP-1 RA added to insulin therapy 63
64 Post-test ARS Question 4 A 49-year-old man with 10-year history of T2DM and NSTEMI 2 years ago works on a farm and has long active days. His A1C is 7.8%, FBG mg/dl and PPG mg/dl. Meds include metformin 1000 mg bid and basal insulin 38 U qam. Which of the following might be appropriate to manage hyperglycemia and cardiovascular risk? 1. Add sulfonylurea 2. Add rapid-acting insulin before each meal 3. Discontinue basal insulin and start GLP-1RA 4. Add GLP-1RA and reduce dose of basal insulin 64
65 Post-test ARS Question 5 When adjusting therapy in patients with type 2 diabetes, as a result of attending this program, how often will you consider using GLP-1 receptor agonists in combination with basal insulin: 1. Never 2. Rarely 3. Sometimes 4. Often 5. Always 65
66 Post-test ARS Question 6 Please rate your confidence in your ability to utilize GLP-1RAs in clinical practice: 1. Not at all confident 2. Slightly confident 3. Moderately confident 4. Pretty much confident 5. Very confident 66
Diabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More information9/6/18. Clinical Updates for Nurse Practitioners and Physician Assistants: Faculty. Disclosures
Clinical Updates for Nurse Practitioners and Physician Assistants: 218 Combination Basal Insulin and GLP-1 RA Therapy: A Physiologic Approach to Diabetes Care Faculty Robert S. Busch, MD, FACE Director
More information10/15/18. Clinical Updates for Nurse Practitioners and Physician Assistants: Faculty. Disclosures
Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 Combination Basal Insulin and GLP-1 RA Therapy: A Physiologic Approach to Diabetes Care Faculty Robert S. Busch, MD, FACE Director
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationBasal & GLP-1 Fixed Combination Use
Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationADA and AACE Glycemic Targets
ADA and AACE Glycemic Targets HbA1C target should be individualized based on a number of factors including: Age Life expectancy Comorbidities Duration of diabetes Risk of hypoglycemia Patient motivation
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationThe Highlights of the AWARD Clinical Program FRANCESCO GIORGINO
The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO DEPARTMENT OF EMERGENCY AND ORGAN TRANSPLANTATION SECTION OF INTERNAL MEDICINE, ENDOCRINOLOGY, ANDROLOGY AND METABOLIC DISEASES Disclaimer
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationCombination treatment for T2DM
Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationInjectable Agents for Type 2 Diabetes. Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017
Injectable Agents for Type 2 Diabetes Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017 Financial Disclosures Sanofi speaker honoraria No other relevant financial disclosures Injectable
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationOptimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes
Optimizing Treatment Strategies to Improve Patient Outcomes in the Management of Type 2 Diabetes Philip Raskin, MD Professor of Medicine The University of Texas, Southwestern Medical Center NAMCP Spring
More informationGLP-1-based therapies in the management of type 2 diabetes
GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin
More informationMYTH VS FACT #1: GLP-1 RECEPTOR AGONISTS SHOULD BE RESERVED FOR PATIENTS WITH LONG-STANDING T2DM
9:45 11: AM Separating Myth from Fact: The Role of Receptor Agonists for the Treatment of T2DM SPEAKERS James R. Gavin, III, MD, PhD John E. Anderson, MD Presenter Disclosure Information The following
More informationNew Drug Evaluation: lixisenatide injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationQuando l insulina basale non basta più: differenti e nuove strategie terapeutiche
Quando l insulina basale non basta più: differenti e nuove strategie terapeutiche Giorgio Sesti Università Magna Graecia di Catanzaro Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationPresented By: Creative Educational Concepts, Inc. Lexington, KY
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of April 2015. The content and views presented in this educational activity are those of the
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationAlbiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
St. Onge et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 10 REVIEW ARTICLE Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St. Onge 1*, Shannon
More informationADA Analyst Presentation Saturday 9 th June
ADA Analyst Presentation Saturday 9 th June Carlo Russo Senior Vice-President & Albiglutide Team Leader, GSK Property of GlaxoSmithKline Agenda Welcome & introduction to the Harmony Clinical Programme
More informationProgressive Loss of β-cell Function in T2DM
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationPramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon
Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
Learning Objectives Understand and appropriately individualize treatments based on evidencebased guideline recommendations across the continuum of care in patients with T2DM Key = Clinical Pearl Identify
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationBedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L
Diabetes Ther (2018) 9:2155 2162 https://doi.org/10.1007/s13300-018-0507-0 BRIEF REPORT Bedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L Ariel Zisman.
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationSelecting GLP-1 RA Treatment
Selecting GLP-1 RA Treatment Dr Felicity Kaplan March 2017 Objectives Review the progressive nature of type 2 diabetes Understand the need for timely treatment intensification Examine the place of GLP-1
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationPHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL
Dr Aurora Alcantara Endocrinology PHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL SPED Convention and Diabetes Postgraduate Course May26-29 Wyndham Grand Rio Mar, PR DISCLOSURES Speaker for the following
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationCombatting T2DM Clinical Inertia: Evaluating the Evidence For Simultaneous Basal Insulin and GLP 1 Receptor Agonists
Combatting T2DM Clinical Inertia: Evaluating the Evidence For Simultaneous Basal Insulin and GLP 1 Receptor Agonists Developed in Collaboration Instructions to Receive Credit To receive credit for your
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationThe Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center
The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection
More informationNew Drug Evaluation: Dulaglutide
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationActivity Overview. Target Audience
Activity Overview In this Webinar, experts in endocrinology and primary care present clinical evidence and answer participant questions regarding insulin intensification with glucagon-like peptide-1 receptor
More informationAdlyxin. (lixisenatide) New Product Slideshow
Adlyxin (lixisenatide) New Product Slideshow Introduction Brand name: Adlyxin Generic name: Lixisenatide Pharmacological class: Glucagon-like peptide-1 (GLP-1) receptor agonist Strength and Formulation:
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationEmerging Challenges in Primary Care: The Progression of Type 2 Diabetes: A Rational Approach for Long-term Disease Management
Emerging Challenges in Primary Care: 2018 The Progression of Type 2 Diabetes: A Rational Approach for Long-term Disease Management 1 Faculty Rodolfo J. Galindo, MD Assistant Professor of Medicine Emory
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationWhat s New? An Antihyperglycemic Medications Update
What s New? An Antihyperglycemic Medications Update WADE 2016 Annual Conference Josh Neumiller, PharmD, CDE, FASCP Associate Professor Department of Pharmacotherapy Washington State University Disclosures
More informationGLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationNew Treatment Options for Type 2 Diabetes: Incretin-Based Therapy
New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy is supported by an educational grant from Novo Nordisk Inc. This program
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationGLP-1 Agonists for Diabetes
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationFaculty FACULTY DISCLOSURES. - Advisor/Consultant Boehringer Ingelheim, Sanofi Aventis, Daiichi Sankyo, Lilly, Novo Nordisk, Takeda, Janssen
Getting Comfortable with Injectable Therapies for Diabetes: A Two-Way Discussion Getting Comfortable with Injectable Therapies for Diabetes: A Two-Way Discussion Emerging Challenges In Primary Care: 2014!
More informationInsulin and Post Prandial
Insulin and Post Prandial Pr Luc Martinez PCDE Meeting Barcelona 2016 Conflicts of interest disclosure Advis consultant f Amgen Inc.; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Ipsen; Lilly; Mayoly
More information